Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

DPH treatment

YD Yashodhara Dasgupta
MK Mateusz Koptyra
GH Grazyna Hoser
KK Kanchan Kantekure
DR Darshan Roy
BG Barbara Gornicka
MN Margaret Nieborowska-Skorska
EB Elisabeth Bolton-Gillespie
SC Sabine Cerny-Reiterer
MM Markus Müschen
PV Peter Valent
MW Mariusz A. Wasik
CR Christine Richardson
OH Oliver Hantschel
HK Heiko van der Kuip
TS Tomasz Stoklosa
TS Tomasz Skorski
request Request a Protocol
ask Ask a question
Favorite

CML-CP cells from freshly diagnosed patients, B-ALL xenograft cells, Baf3-TEL-ABL1 cell lines, and murine BMCs expressing NUP214-ABL1 oncogene were treated with 5-[3-(4-fluorophenyl)-1-phenylpyrazol-4-yl]imidazolidine-2,4-dione (DPH; Sigma-Aldrich), imatinib and ponatinib (both from Selleck Chemicals) and evaluated as described in supplemental Methods. These studies were approved by the Temple University institutional review board.

Copyright and License information:  ©2016 by The American Society of Hematology

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A